Chinese biotech start-up BioTroy Therapeutics has raised over 200 million renmnibi ($28 million) in series A financing to advance clinical trials for its experimental immunotherapy targeting CD3L1, a ...

SunRock Biopharma has teamed up with China’s Escugen to co-develop SRB123, a first-in-class antibody-drug conjugate (ADC) targeting CCR9, an antigen which is tied to particularly hard-to-treat cancers ...

US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...

US biopharma Mineralys Therapeutics has announced positive topline data from its Phase II Explore-CKD trial evaluating the ...

EY today released its 35th annual Biotech Beyond Borders Report. This finds that the biopharma industry is currently at an ...

The UK’s National Institute for Health and Care Excellence (NICE) has today recommended Spevigo (spesolimab) for the ...

Cambridge, USA-based Immuneering Corporation late yesterday announced positive data from its ongoing Phase IIa clinical trial evaluating atebimetinib (IMM-1-104), an oral, once-daily novel MEK ...

The US Food and Drug Administration has announced the Commissioner’s National Priority Voucher (CNPV) program aimed at ...

Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric ...

US pharma firm Lisata Therapeutics (Nasdaq: LSTA) has teamed up with tech-bio company GATC Health in a strategic alliance ...

US biotech Dyne Therapeutics (Nasdaq: DYN) has revised its regulatory approach for DYNE-101, a treatment in development for ...

A controversial proposal to change the Inflation Reduction Act’s pricing framework for rare disease drugs has been dropped ...